Theses library
Trackable hypotheses surfaced by Weekly. Each thesis carries the week it opened and a running record of supporting and countering evidence.
How we judge
- ACTIVE
Default state. Both supporting and counter-evidence accumulate; the thesis is reviewed at every weekly publication.
- VALIDATED
Supporting evidence accrues for four or more consecutive weeks with no decisive counter-evidence, and the thesis is now widely accepted in its field.
- FALSIFIED
Triggered by any of: ① a primary source directly refutes the claim, ② core supporting evidence is corrected or retracted, or ③ four consecutive weeks of dominant counter-evidence.
- SUPERSEDED
A newer, more general or more precise thesis subsumes the same territory. The original card pins the replacing thesis ID and stops updating.
Trenri tracks and contextualizes — it does not endorse. Status is reviewed every Monday at the weekly publication, based on the accumulated record.
Global monetary policy fragments asymmetrically into five tracks
Fed's 8-4 split hold, BOJ's ¥5.48 trillion intervention, ECB's hawkish pivot, Norges Bank's surprise 25bp hike, and BLS's 115k payrolls surprise align in the same quarter, fragmenting global monetary policy coordinates into five asymmetric tracks. This fragmentation itself has become a first-order variable for capital flows, exchange rates, and asset prices.
AI capex eclipses geopolitical shock
Major indices react faster and more sharply to AI infrastructure investment decisions than to Strait of Hormuz blockade or Middle East war headlines. The 'war premium' cannot keep pace with the pricing power of the 'AI supercycle'.
AI Capital Acceleration Directly Erodes White-Collar Payroll Costs
Big Tech and SaaS firms are converting AI capex directly into headcount cuts as a capital move. This is no longer cost reduction in isolation; the accounting model has normalized "AI capital = payroll reduction" as standard practice.
GLP-1 market enters triple inflection point: oral agents, insurance cliff, and end of 503B compounding
The obesity treatment category is shifting from a single injectable market to a three-axis simultaneous transition: oral medication market share wars (Foundayo, Wegovy pill), a 12-million-person insurance coverage cliff, and the end of 503B compounding—reorganizing into a price and access game around who reaches routine prescription first.
A single Hormuz shock closes the loop: energy, consumption, and monetary policy
Iran war and Hormuz blockade bind gas prices → headline CPI → Fed rate cut bets into a single channel. This feedback loop has become the quarterly macro price-setter.